Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol

Introduction Chronic Myeloid Leukaemia (CML) constitutes 15% of new adult leukaemia cases as well as 2%–3% of leukaemia in children under 15% and 9% of leukaemias in adolescents 15–19 years of age annually. The introduction of Tyrosine Kinase Inhibitors (TKI) therapy has dramatically improved surviv...

Full description

Bibliographic Details

Published in:	BMJ Open
Main Authors:	M Constantine Samaan, Lehana Thabane, Laura Banfield, Janatani Balakumaran, Tanisha Birk, Breanne Golemiec, Wryan Helmeczi, Jeyanth Inkaran, Yun-ya Kao, Jennifer Leigh, Sarah Saliba, Rishi Sharma, Laura Spatafora, Kristin Wright, William Yao, Christopher Hillis, Uma Athale
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2019-09-01
Online Access:	https://bmjopen.bmj.com/content/9/9/e030092.full